Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Cash & Current Investments (2016 - 2025)

Wave Life Sciences' Cash & Current Investments history spans 11 years, with the latest figure at $602.1 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 99.32% year-over-year to $602.1 million; the TTM value through Dec 2025 reached $602.1 million, up 99.32%, while the annual FY2025 figure was $602.1 million, 99.32% up from the prior year.
  • Cash & Current Investments reached $602.1 million in Q4 2025 per WVE's latest filing, up from $196.2 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $602.1 million in Q4 2025 to a low of $88.5 million in Q4 2022.
  • Average Cash & Current Investments over 5 years is $197.8 million, with a median of $163.5 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: plummeted 42.74% in 2021, then skyrocketed 126.39% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $150.6 million in 2021, then tumbled by 41.22% to $88.5 million in 2022, then skyrocketed by 126.39% to $200.4 million in 2023, then surged by 50.77% to $302.1 million in 2024, then skyrocketed by 99.32% to $602.1 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Cash & Current Investments are $602.1 million (Q4 2025), $196.2 million (Q3 2025), and $208.5 million (Q2 2025).